Massive claims study aims to validate Real-World evidence for heart failure drugs

NCT ID NCT07599293

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This study uses healthcare claims data from nearly 40,000 people to see if the results of a major clinical trial (EMPEROR-Preserved) can be reproduced in a real-world setting. Researchers are comparing two diabetes drugs, empagliflozin and sitagliptin, in patients with heart failure with preserved ejection fraction and type 2 diabetes. The goal is to learn when real-world data can be trusted to answer clinical questions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Empagliflozin and sitagliptin
What this could lead to
If successful, this could show that analyzing real-world data can reliably replace or supplement traditional clinical trials for certain questions.
What could go wrong
This is an observational study, not a controlled experiment, so results may be biased or not match the original trial. It cannot prove cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Brigham and Women's Hospital

    Boston, Massachusetts, 02120, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.